Market research
GLYC GlycoMimetics Inc
NASDAQ USD Healthcare
Latest close
As of 09 Jul 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- 1.6
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 10M
- P/E ratio
- Not available
- Analyst target
- 1
- Dividend yield
- Not available
- Beta
- 1.6
About
About GlycoMimetics Inc
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
Research context
GlycoMimetics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the GLYC discussion.
5 years, 7 months ago
GlycoMimetics, Inc is currently in a long term downtrend where the price is trading 32.3% below its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.3.
GlycoMimetics, Inc's total revenue rose by inf% to $163K since the same quarter in the previous year.
Its net income has dropped by 5.7% to $-16M since the same quarter in the previous year.
Finally, its free cash flow grew by 24.1% to $-10M since the same quarter in the previous year.
Based on the above factors, GlycoMimetics, Inc gets an overall score of 3/5.